Weight Gain Associated with Antidepressant Treatment

Introduction to Weight Effects

Selective serotonin reuptake inhibitors (SSRIs) like escitalopram can be associated with weight gain, though the effect varies between medications in this class, according to clinical guidelines from the American Diabetes Association 1, 2

Within the SSRI class, paroxetine has the highest risk of weight gain, while fluoxetine and sertraline are typically associated with initial weight loss followed by weight neutrality with long-term use, as reported by the American College of Clinical Pharmacy 2, 3
Bupropion is the only antidepressant consistently shown to promote weight loss through appetite suppression and reduced food cravings, as noted by the American College of Clinical Pharmacy 2

For patients with significant concerns about weight gain, consider choosing a more weight-neutral option like fluoxetine or a weight-loss promoting option like bupropion if clinically appropriate, as suggested by the American College of Clinical Pharmacy 2
Implementing dietary counseling and physical activity recommendations at treatment initiation can help mitigate weight gain, according to the American Gastroenterological Association 4
Medications for comorbid conditions may also contribute to weight gain and should be minimized when possible, as recommended by the American Diabetes Association 1

Mirtazapine and amitriptyline carry the greatest weight gain risk among their respective classes, according to the JAMA 5
The American Diabetes Association recommends reviewing all concomitant medications that may contribute to weight gain, as reported in JAMA 5

The American Academy of Child and Adolescent Psychiatry recommends regular monitoring of weight and growth in pediatric patients taking SSRIs, as decreased appetite and weight loss have been observed 6
Gastrointestinal side effects, such as nausea and decreased appetite, can contribute to weight loss in early treatment phases, according to the American Family Physician and the Journal of the American Academy of Child and Adolescent Psychiatry 7, 6
The Gastroenterology journal notes that concomitant medications, such as antidiabetics, antihypertensives, and antipsychotics, may contribute to weight gain 8

Mirtazapine, amitriptyline, and MAO inhibitors are closely associated with significant weight gain, according to the American Diabetes Association, as reported in Diabetes Care 9
The American Diabetes Association recommends monitoring weight at baseline, monthly for the first 3 months, then quarterly during continued treatment, as reported in Diabetes Care 9
Minimizing concomitant medications associated with weight gain, such as antipsychotics, some anticonvulsants like gabapentin/pregabalin, and glucocorticoids, is advised by the American Diabetes Association, as reported in Diabetes Care 9

The American Diabetes Association suggests avoiding paroxetine, duloxetine, mirtazapine, and tricyclic antidepressants in weight-concerned patients, as reported in Diabetes Care 9

Within the SSRI class, escitalopram carries a moderate risk of weight gain—lower than paroxetine (the highest‑risk SSRI) but slightly higher than fluoxetine or sertraline, which are essentially weight‑neutral. 10
Fluoxetine and sertraline are associated with an initial modest weight loss that stabilizes to weight neutrality with long‑term use, making them preferable when minimizing weight change is a priority. 10
Bupropion is the only antidepressant consistently shown to produce weight loss through appetite suppression and reduced food cravings. 10
In patients with obesity, metabolic syndrome, or type 2 diabetes, the preferred pharmacologic options are bupropion (weight‑loss promoting) or sertraline/fluoxetine (weight‑neutral). 10
When anxiety symptoms limit the use of bupropion because of its activating properties, sertraline or fluoxetine provide better weight‑neutral alternatives than escitalopram. 10
Weight gain in psychiatric patients is often multifactorial; concomitant medications such as antipsychotics, anticonvulsants, or glucocorticoids may contribute more to weight change than the antidepressant itself. 10

In patients with established cardiovascular disease who require antidepressant therapy, escitalopram is considered safe, although sertraline has been studied more extensively and is associated with a lower risk of QTc interval prolongation. (American Heart Association) 11
The modest weight gain observed with escitalopram is unlikely to have a meaningful adverse impact on cardiovascular risk profiles relative to its mental‑health benefits. (American Heart Association) 11
In post‑acute coronary syndrome cohorts, escitalopram was linked to a lower incidence of major adverse cardiovascular events (MACE) over a median follow‑up of 8.1 years (40.9 % vs 53.6 % with comparator therapy), but it carries a higher QTc prolongation risk compared with sertraline. (American College of Cardiology) 12